Xapien's $56M Due-Diligence Round: A Real Theme With No Public Ticket

Spectrum Equity, a growth investor with a track record in compliance software, just put $56 million into a London startup called Xapien in a Series B round. The headline reads like another AI funding story. Look at what the company actually does and it becomes more specific: it is a bet that "due diligence" is about to stop being a one-time background check and become a continuous, always-on product.

Traditional due diligence is a snapshot. Before a bank takes on a client or a company signs a supplier, someone runs a check, files the report, and moves on until the next review. Xapien's founders came out of BAE Systems' financial-crime and national-security divisions, and what they built replaces that single check with an AI platform that keeps watching a counterparty and flagging changes as they happen. Xapien calls it "dynamic due diligence."

The size of the check is not the part worth dwelling on. The reason this money is chasing the problem at all is.

Financial institutions do not run these checks because they want to. They run them because regulators require it, and the cost of getting it wrong is a fine. That is the engine under the entire category. One forecast sizes the US market for anti-money-laundering software at $936.7 million in 2025 and projects it to roughly double to about $2.06 billion by 2030 — a compound growth rate near 17% — driven by FinCEN mandates and Bank Secrecy Act enforcement. That is a base of recurring compliance spending, and it is recurring because the requirement never disappears.

Xapien says the US already accounts for half its revenue, and it counts Greenberg Traurig, ABB, Dow Jones Risk & Compliance and KPMG among 350 clients and partners across 15 countries. The new money is earmarked to push deeper into the US: grow the Boston office and move the CEO and senior leaders stateside.

Why does a specialist like Spectrum care? Because it has profited from this category before. It backed Verafin, the anti-financial-crime platform that exchange operator Nasdaq bought for $2.75 billion in cash, and it is tied to World-Check, an entrenched name in due-diligence data. A backer with a proven exit path is what separates a plausible story from one that can actually reach an IPO or a trade sale.

Now the honest catch, and it is the part worth sitting with: you cannot buy Xapien. It is a private company — no public shares, no quarterly filings, no revenue or margin disclosure, and no free cash flow to inspect. A $56 million funding round is private markets pricing a narrative. In my discipline, free cash flow is the hard proof of a story; when it is unavailable, I name the alternative anchor and demand more caution. Here the anchor is a customer count and a revenue split, and that is a thinner reed than a cash-flow statement.

It is also the wrong corner of the market for how I look for entries. I hunt for businesses the market has given up on while the numbers quietly improve underneath — an expectations reset that gives you room for surprise. Xapien is the reverse: a red-hot AI category, priced with enthusiasm, with no public financials to confirm that the numbers behind the enthusiasm are real. When private money pays up for growth, there is no beaten-down expectation protecting you. You are buying the optimistic case at the going rate.

The theme, though, is real and investable — just not through Xapien. The same demand for vetting people and companies shows up inside public businesses that actually report cash flow. Nasdaq now owns Verafin outright. Moody's sells third-party risk and entity-intelligence data, and names like Experian, Wolters Kluwer and Thomson Reuters all sit in the neighborhood. But in each of those, due-diligence software is a sliver of a large, diversified operation, and its cash flow is diluted inside the whole. There is no clean public pure-play — which is itself the point. This is a real, regulated tailwind that a retail investor can only own through blunt instruments.

The strongest bear case for the theme is that the incumbents hold the moat. Data-rich names like Dow Jones and Thomson Reuters already control much of the underlying risk intelligence, and if the AI entrants can only automate labor instead of owning durable margins, the excitement fades. What you can check from the public seat is whether the incumbents — which publish real free cash flow — are actually turning this compliance tailwind into rising cash generation. That is the metric that proves or falsifies the whole story.

So the $56 million is a data point, not a buy signal — nothing here is directly buyable by a typical retail investor. What it usefully does is put the due-diligence theme on the radar and show what that theme costs at full private-market prices. For anyone making their own decision, the disciplined move is not to chase Xapien's valuation but to open the cash-flow statements of the public businesses already harvesting this same regulatory demand, and ask whether the free cash flow is actually arriving. That is the proof that matters.